已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

无容量 易普利姆玛 医学 内科学 肿瘤科 结直肠癌 微卫星不稳定性 转移性黑色素瘤 癌症 癌症研究 免疫疗法 生物 遗传学 等位基因 微卫星 基因
作者
Thierry André,Elena Élez,Eric Van Cutsem,Lars Henrik Jensen,Jaafar Bennouna,Guillermo Ariel Mendez,Michael Schenker,Christelle de la Fouchardière,María Luisa Limón,Takayuki Yoshino,Jin Li,Heinz‐Josef Lenz,José Luis Manzano Mozo,Giampaolo Tortora,Rocio García‐Carbonero,Laëtitia Dahan,Myriam Chalabi,Rohit Joshi,Eray Goekkurt,Maria Ignez Braghiroli
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:391 (21): 2014-2026 被引量:285
标识
DOI:10.1056/nejmoa2402141
摘要

BACKGROUND: Patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapies. Nivolumab plus ipilimumab has shown clinical benefit in nonrandomized studies of MSI-H or dMMR metastatic colorectal cancer. METHODS: In this phase 3 open-label trial, we randomly assigned patients with unresectable or metastatic colorectal cancer and MSI-H or dMMR status according to local testing to receive, in a 2:2:1 ratio, nivolumab plus ipilimumab, nivolumab alone, or chemotherapy with or without targeted therapies. The dual primary end points, assessed in patients with centrally confirmed MSI-H or dMMR status, were progression-free survival with nivolumab plus ipilimumab as compared with chemotherapy as first-line therapy and progression-free survival with nivolumab plus ipilimumab as compared with nivolumab alone in patients regardless of previous systemic treatment for metastatic disease. At this prespecified interim analysis, the first primary end point (involving nivolumab plus ipilimumab vs. chemotherapy) was assessed. RESULTS: A total of 303 patients who had not previously received systemic treatment for metastatic disease were randomly assigned to receive nivolumab plus ipilimumab or chemotherapy; 255 patients had centrally confirmed MSI-H or dMMR tumors. At a median follow-up of 31.5 months (range, 6.1 to 48.4), progression-free survival outcomes (the primary analysis) were significantly better with nivolumab plus ipilimumab than with chemotherapy (P<0.001 for the between-group difference in progression-free survival, calculated with the use of a two-sided stratified log-rank test); 24-month progression-free survival was 72% (95% confidence interval [CI], 64 to 79) with nivolumab plus ipilimumab as compared with 14% (95% CI, 6 to 25) with chemotherapy. At 24 months, the restricted mean survival time was 10.6 months (95% CI, 8.4 to 12.9) longer with nivolumab plus ipilimumab than with chemotherapy, a finding consistent with the primary analysis of progression-free survival. Grade 3 or 4 treatment-related adverse events occurred in 23% of the patients in the nivolumab-plus-ipilimumab group and in 48% of the patients in the chemotherapy group. CONCLUSIONS: Progression-free survival was longer with nivolumab plus ipilimumab than with chemotherapy among patients who had not previously received systemic treatment for MSI-H or dMMR metastatic colorectal cancer. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 8HW ClinicalTrials.gov number, NCT04008030.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
共享精神的应助被俭朴灵竹采纳,获得10
刚刚
倾解完成签到,获得积分10
刚刚
星星完成签到 ,获得积分10
4秒前
5秒前
寒冷水香完成签到,获得积分10
5秒前
7秒前
8秒前
9秒前
斯文败类的应助被zxinran0408采纳,获得10
11秒前
大模型的应助被Okpooko采纳,获得10
11秒前
专一的白发布了新的文献求助10
11秒前
Tenax完成签到,获得积分10
12秒前
强健的秋发布了新的文献求助10
12秒前
Owen的应助被Tohka采纳,获得10
13秒前
无花果的应助被奋斗易真采纳,获得10
13秒前
Ava的应助被zuuyo采纳,获得10
13秒前
漂亮的大碗完成签到,获得积分20
15秒前
优秀绝悟完成签到,获得积分10
15秒前
16秒前
17秒前
18秒前
20秒前
李灿完成签到 ,获得积分10
21秒前
浩懿一发布了新的文献求助10
21秒前
21秒前
ihxy完成签到,获得积分10
22秒前
lee发布了新的文献求助10
23秒前
车仔面关注了科研通微信公众号
23秒前
23秒前
zyj发布了新的文献求助10
23秒前
梦自然完成签到 ,获得积分10
24秒前
Okpooko发布了新的文献求助10
24秒前
我是老大的应助被圈圈采纳,获得10
24秒前
倾解关注了科研通微信公众号
24秒前
柯梦晓关注了科研通微信公众号
24秒前
25秒前
26秒前
小豆糕发布了新的文献求助10
26秒前
27秒前
田様的应助被科研通管家采纳,获得10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184646
求助须知:如何正确求助?哪些是违规求助? 9573637
关于积分的说明 21832477
捐赠科研通 7781914
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003